ReviewFrontiers in immunology2023
Vaccine development for mosquito-borne viral diseases.
Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Synthesis, Structure-Activity Considerations and Histopathological Effects of Diborane Derivatives as Mosquito Larvicides.Acta parasitologica · 2026Article
- Revisiting Animal Reservoirs of Hantavirus and Other Zoonotic Viruses Associated with Cruise Travel: Impact and Prevention.Animals : an open access journal from MDPI · 2026Review
- Achievements and Challenges in Therapy and Vaccines Development of Viral Hemorrhagic Fevers: An Up-to-Date Review.Pharmaceutics · 2026Review
- Integrated transcriptome-microbiome analysis reveals a host-microbe interplay associated with insecticide resistance inFrontiers in microbiology · 2026Article
- The shift in Mosquito-borne diseases incidence across Asia-Pacific region (1992-2021): insights from an Age-Period-Cohort analysis using the global burden of disease study 2021.BMC public health · 2025Article
- Gold nanoparticle-based delivery of Cas13d for targeted RNA virus defense.Molecular therapy. Nucleic acids · 2025Article
- The potential and challenges of circular RNA in the development of vaccines and drugs for emerging infectious diseases.Molecular therapy. Nucleic acids · 2025Review
- Virome profiling of Aedes albopictus across urban ecosystems in Guangdong reveals sex-specific diversity.Parasites & vectors · 2025Article
- Knowledge, attitude, and practice (KAP), and acceptance and willingness to pay (WTP) for mosquito-borne diseases control through sterile mosquito release in Bangkok, Thailand.PLoS neglected tropical diseases · 2025Article
- Fighting RNA viruses with a gold nanoparticle Cas13d gene-editing armor.Molecular therapy. Nucleic acids · 2025Article
- Lysinibacillus sphaericus exposure impedes Anopheles dirus's oviposition via downregulating vitellogenin.Parasites & vectors · 2025Article
- Research progress of mosquito-borne virus mRNA vaccines.Molecular therapy. Methods & clinical development · 2025Review
- Insect-specific viruses: transmission dynamics and biological control strategies against arboviruses.Frontiers in microbiology · 2025Review
- A novel pan-epitope based nanovaccine self-assembled with CpG enhances immune responses against flavivirus.Journal of nanobiotechnology · 2024Article
- Review
- Trends and insights in dengue virus research globally: a bibliometric analysis (1995-2023).Journal of translational medicine · 2024Article
- A review on Zika vaccine development.Pathogens and disease · 2024Review
- Review
- Mosquito Salivary Antigens and Their Relationship to Dengue andPathogens (Basel, Switzerland) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mosquito-borne viral diseases are a group of viral illnesses that are predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families. In recent years, outbreaks caused by Dengue and Zika viruses from the Flaviviridae family, and Chikungunya virus from the Togaviridae family, have raised significant concerns for public health. However, there are currently no safe and effective vaccines available for these viruses, except for CYD-TDV, which has been licensed for Dengue virus. Efforts to control the transmission of COVID-19, such as home quarantine and travel restrictions, have somewhat limited the spread of mosquito-borne viral diseases. Several vaccine platforms, including inactivated vaccines, viral-vector vaccines, live attenuated vaccines, protein vaccines, and nucleic acid vaccines, are being developed to combat these viruses. This review analyzes the various vaccine platforms against Dengue, Zika, and Chikungunya viruses and provides valuable insights for responding to potential outbreaks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.